Department of Obstetrics and Gynecology, University of Utah, 30N 1900E, Room 2B200, Salt Lake City, UT 84132, USA.
J Reprod Immunol. 2010 Jun;85(2):180-5. doi: 10.1016/j.jri.2010.03.007. Epub 2010 May 2.
Antiphospholipid antibodies are associated with a spectrum of pregnancy complications, including preeclampsia and small for gestational age (SGA) fetuses. We sought to assess anticardiolipin and anti-beta2-glycoprotein I (anti-beta2-GPI) IgG and IgM antibody prevalence and the relationship of these antibodies to pregnancy complications in women with the Factor V Leiden (FVL) mutation. The study comprised a secondary analysis of a multicenter, prospective observational study of FVL prevalence among 5188 asymptomatic pregnant women. A subset of 362 women (117 FVL heterozygotes, 245 matched controls) had serum collected at the time of the original study and underwent serum analysis for anticardiolipin and anti-beta2-GPI IgG and IgM as a part of this analysis. The primary outcome was preeclampsia and/or SGA (<10%). The overall prevalence of anticardiolipin and anti-beta2-GPI IgG and IgM antibodies was low and did not vary with FVL status. Forty-seven women (13.0%) developed preeclampsia and/or SGA. There were no differences in primary outcome rates between women with and without aPL antibodies, regardless of FVL mutation status. Among FVL carriers, the presence of antiphospholipid antibodies does not appear to contribute to adverse pregnancy outcome.
抗磷脂抗体与一系列妊娠并发症相关，包括子痫前期和胎儿生长受限（SGA）。我们旨在评估携带因子 V 莱顿（FVL）突变的女性中抗心磷脂和抗β2-糖蛋白 I（抗β2-GPI）IgG 和 IgM 抗体的流行率以及这些抗体与妊娠并发症的关系。该研究是对 5188 例无症状孕妇中 FVL 流行率的多中心前瞻性观察研究的二次分析。362 名女性（117 名 FVL 杂合子，245 名匹配对照）的一部分在原始研究时采集了血清，并进行了血清分析，以作为本分析的一部分检测抗心磷脂和抗β2-GPI IgG 和 IgM。主要结局是子痫前期和/或 SGA（<10%）。抗心磷脂和抗β2-GPI IgG 和 IgM 抗体的总体流行率较低，且不受 FVL 状态的影响。47 名女性（13.0%）发生了子痫前期和/或 SGA。无论 FVL 突变状态如何，有无抗磷脂抗体的女性主要结局发生率均无差异。在 FVL 携带者中，抗磷脂抗体的存在似乎不会导致不良妊娠结局。
